Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
BioClinica®, Inc., a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and lead discussions at several upcoming industry conferences in January, February, and March. ...
read more
Thursday, January 05, 2023
Biognosys AG and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed.
read more
Tuesday, January 06, 2015
Timothy Callahan, Ph.D., chief medical officer of Biomedical Systems, a premier, global provider of centralized diagnostic services, spoke on “Cardiac Safety in the Post E14 Era” at a recent seminar in Suzhou, China.
read more
Tuesday, November 03, 2015
Cytovance Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a ...
read more
Bios Health Group entered into the Life Science market to help biotech entrepreneurs and executives take their innovative ideas to the next level.
read more
BioStem Technologies Inc., a pre-clinical-stage biotechnology company focused on elements of perinatal tissue for use in regenerative therapies; announced that it has engaged Biologics Consulting, a full-service regulatory and product development ...
read more
BioStorage Technologies, a global provider of comprehensive sample management solutions for the bioscience industry, including storage, cold chain logistics and virtual sample intelligence, will host its European Global Sample Management Benchmarking...
read more
In order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug ...
read more
Tuesday, February 21, 2012
Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal ...
read more
Wednesday, February 11, 2015
Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement. VTU ...
read more
Boehringer Ingelheim and Eli Lilly announced a research collaboration with DCRI for the prevention of Chronic heart failure and mortality after an acute Myocardial Infarction.
read more
Tuesday, October 24, 2017
Bracket announced the acquisition of mProve Health, a provider of mobile technologies for life science companies.
read more
Tuesday, October 17, 2017
Cadent Therapeutics has earned a milestone payment for the initiation of a Phase 1 clinical study of a subtype selective NMDA receptor negative allosteric modulator for treatment-resistant depression.
read more
Thursday, February 28, 2013
Camargo Pharmaceutical Services, the 505(b)(2) experts, is teaming with XenoTech, a leading contract research organization in the drug metabolism field, to present a webinar March 21 for drug developers who want to learn how to use the 505(b)(2) ...
read more
Cardinal Health announced it has been awarded a $750,000 contract by the FDA to implement an 18-month real world evidence (RWE) study as part of the agency's efforts to advance the applicability of RWE in regulatory decision-making.
read more